Nanobiotix (NBTX) Stock Price, News & Analysis

Company Overview

Nanobiotix is a biotechnology company developing nanoparticle-based therapies designed to improve the effectiveness of radiotherapy in cancer treatment. The company’s technology uses hafnium oxide nanoparticles that are injected directly into a tumor and activated by ionizing radiation, with the goal of increasing energy deposition within cancer cells while limiting exposure to surrounding tissue.

Nanobiotix’s lead product candidate, NBTXR3, is being evaluated in clinical studies across several cancer types, including locally advanced head and neck cancer and other solid tumors. The company has investigated NBTXR3 in combination with radiotherapy, chemotherapy, and immunotherapies. Its radioenhancer received European CE marking under the name Hensify for use with radiotherapy in certain patients with locally advanced soft-tissue sarcoma, although the company continues to study broader applications.

Founded in 2003 and headquartered in France, Nanobiotix conducts development activities internationally, including clinical research in Europe, the United States, and other regions. The company has collaborated with Janssen Biotech, a Johnson & Johnson company, on the development of NBTXR3 in immuno-oncology. Nanobiotix was co-founded by Laurent Levy, who serves as chief executive officer and chairman of the management board.

Key Stats

• Today's Range: $32.35 to $34.11
• 50-Day Range: $21.08 to $45.16
• 52-Week Range: $17.37 to $57.14
• Volume: 85,569 shs
• Average Volume: 139,547 shs
• Market Capitalization: $1.72 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $46.67
• Consensus Rating: Moderate Buy

Nanobiotix Stock Analysis - MarketRank™

Nanobiotix scored higher than 60% of companies evaluated by MarketBeat, and ranked 397th out of 904 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Nanobiotix has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 4 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Nanobiotix has a consensus price target of $46.67, representing about 38.1% upside from its current price of $33.80.

Amount of Analyst Coverage

Nanobiotix has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Nanobiotix are expected to grow in the coming year, from ($0.62) to $0.16 per share.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.40% of the float of Nanobiotix has been sold short.

Short Interest Ratio / Days to Cover

Nanobiotix has a short interest ratio ("days to cover") of 1.24, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Nanobiotix has recently increased by 33.80%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Nanobiotix does not currently pay a dividend.

Dividend Growth

Nanobiotix does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 0.79

News Sentiment

Nanobiotix has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Nanobiotix this week, compared to 2 articles on an average week.

Search Interest

1 people have searched for NBTX on MarketBeat in the last 30 days.

Company Ownership

• Score: 0.6 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Nanobiotix insiders have not sold or bought any company stock.

Percentage Held by Insiders

3.45% of the stock of Nanobiotix is held by insiders.

Percentage Held by Institutions

38.81% of the stock of Nanobiotix is held by institutions.

Company Calendar

• Last Earnings: 3/31/2026
• Today: 10/29/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:NBTX
• CIK: 1760854
• Web: www.nanobiotix.com
• Phone: 33-1-40-26-04-70
• Fax: N/A
• Employees: 97
• Year Founded: 2003

Price Target and Rating

• Average Price Target for Nanobiotix: $46.67
• High Price Target: $64.00
• Low Price Target: $30.00
• Potential Upside/Downside: +38.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 6 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.44
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $36.87 million
• Price / Sales: 46.60
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.97) per share
• Price / Book: -17.16

Miscellaneous

• Outstanding Shares: 50,830,000
• Free Float: 49,073,000
• Market Cap: $1.72 billion
• Optionable: Optionable
• Beta: 0.79